Convention Hall May 14, 2019 invited abstract
Plenary 10:45 - 12:00

Genome Wide Discoveries in 13,000 Whole Genome Sequenced Rare Disease Cases and Controls
10:50 - 11:20
Presented by : Prof. Willem H Ouwehand

To study genetic sequence variants underlying unresolved Mendelian disorders and improve interpretation of already identified high penetrance variants, a collection of 13,000 individuals with a rare disease and their relatives has been whole genome sequenced with an average 30x coverage. Participants were recruited at 57 National Health Service (NHS) hospitals in the UK and 26 non-UK hospitals using approved eligibility criteria for 15 different rare disease domains.

We describe the population structure including ethnicity and relatedness estimation, high level phenotypes collected using Human Phenotype Ontology (HPO) terms and quality control and summary metrics for samples and variants. The resource contains over 165 million unique variants (including 90, 3 and 6% SNVs, small insertions and deletions respectively) in the 10,258 genetically independent samples with 47% of variants previously unobserved in other large scale publically available genome datasets (e.g. gnomAD, HGMD, UK10K).

We summarise the curation of gene lists and pertinent findings in 2,000 unique diagnostic-grade genes for the 15 domains. Over 1200 reports assigning pathogenic or likely pathogenic causal variants have been issued following review by Multi-Disciplinary Teams. The diagnostic yield varied across the different domains from 0.5 to 55%, while the proportion of novel (compared to HGMD) causal variants ranged between 25 to 73%; causal variants in 10 genes have been reported that involve cross-domain findings, where the same gene is linked to different clinical phenotypes.

We show the power of a recently developed rapid Bayesian association test, BeviMed, to identify novel genes (n>30) and causal variants in the non-coding space of the genome and to provide independent validation of recent rare disease gene discoveries by others.

The rare disease pilot of the 100,000 Genomes Project has shown the feasibility of using whole genome sequencing across a national health system to deliver a molecular diagnosis for patients with inherited rare diseases and how a national resource of genotype accompanied by HPO-coded phenotypes provides a powerful platform for the identification of so far 46 novel diagnostic-grade genes.

Next Generation Healthcare Delivery in the Era of Personalised Medicine – The Experience of a Comprehensive National Health Service (NHS) Genomic Medicine Service
11:20 - 11:50
Presented by : Prof. Sue HILL

•       This talk sets out the English National Health Service (NHS) approach to improving outcomes through greater personalisation of care underpinned by developments in genomics.

•       It reviews how the world-leading 100,000 Genomes Project provided a proof of concept for the mainstream use of Whole Genome Sequencing to inform routine care.

•       It then sets out how the work of the 100,00 Genomes Project and the long history of genomic developments in the NHS have together formed the foundation for  the introduction of a national Genomic Medicine Service. This will provide comprehensive, consistent and equitable access to the full range of genomic testing for country’s entire 55 million population.

•       This new system is integrated across clinical services and is adopting an end-to-end pathway approach to support improvement of outcomes through personalisation of care, particularly in key clinical priority areas. All patients are also given the opportunity to participate in research, benefiting their future care and helping others with their condition.


Discussions


Discussion not started yet.